所有图片(1)
别名:
3-Methyl-5-[(2S)-1-methyl-2-pyrrolidinyl]isoxazole hydrochloride
经验公式（希尔记法）:
C9H14N2O · HCl
推荐产品
质量水平
检测方案
≥98% (HPLC)
形式
powder
储存条件
desiccated
溶解性
H2O: soluble 15 mg/mL
创始人
Abbott
SMILES字符串
Cl.CN1CCC[C@H]1c2cc(C)no2
InChI
1S/C9H14N2O.ClH/c1-7-6-9(12-10-7)8-4-3-5-11(8)2;/h6,8H,3-5H2,1-2H3;1H/t8-;/m0./s1
InChI key
VOXHERKWAIEJQF-QRPNPIFTSA-N
一般描述
ABT-418 is an α4β2 agonist of nicotinic receptors.
应用
ABT-418 [(S)-3-methyl-5-(1 methyl-2-pyrrolidinyl)isoxazole hydrochloride] is a novel neuronal nicotinic acetylcholine receptor (nAChR) ligand with cognitive enhancing and anxiolytic-like activity 3- to 10-fold more potent than (-)-nicotine in rodents. ABT-418 hydrochloride has been used to study new therapeutic approaches for the treatment of Alzheimer′s disease.
ABT-418 hydrochloride has been used as a nicotinic acetylcholine receptor (nAChR) agonist to test its effect on spatial memory improvement in attention deficit hyperactivity disorder (ADHD) rat model
生化/生理作用
Neuronal nicotinic acetylcholine receptor agonist with cognition enhancing and anxiolytic activities.
特点和优势
This compound is featured on the Acetylcholine Receptors (Nicotinic) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
法律信息
Subject to U.S. Patent No. 5409946 and sold under license from Abbott Laboratories.
警示用语：
Danger
危险分类
Acute Tox. 2 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
J D Brioni et al.
Psychopharmacology, 119(4), 368-375 (1995-06-01)
Previous studies have established that ABT-418 [(S)-3-methyl-5-(1 methyl-2-pyrrolidinyl)isoxazole hydrochloride] is a novel neuronal nicotinic acetylcholine receptor (nAChR) ligand with cognitive enhancing and anxiolytic-like activity 3- to 10-fold more potent than (-)-nicotine in rodents. A series of experiments was conducted to
R Nikolov
Drug news & perspectives, 11(4), 248-255 (2004-12-24)
The 5th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy focused on new therapeutic approaches for the treatment of Alzheimer 's disease (AD) based on the latest basic science data. The two major pharmacological principles of cholinergic therapy are 1)
Tianyou Guo et al.
Neuroscience letters, 528(1), 11-15 (2012-09-19)
Impaired learning performance in scholastic settings is a characteristic of attention deficit hyperactivity disorder (ADHD). Our present study compares the effect of a nicotinic acetylcholine receptor (nAChR) agonist, ABT-418, and methylphenidate (MPH) on spatial memory in spontaneously hypertensive rats (SHRs)
J D Brioni et al.
The Journal of pharmacology and experimental therapeutics, 271(1), 353-361 (1994-10-01)
The hydrochloride salt of (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT-418), a potent activator of select subtypes of neuronal nicotinic acetylcholine receptors enhanced retention in memory tests and induced anxiolytic-like effects in mice in the elevated plus maze. In the present studies in rats
Nikolaos Pitsikas
Behavioural brain research, 393, 112778-112778 (2020-06-25)
Several lines of evidence indicate that anesthetic doses of the non-competitive N-methyl-D-aspartate receptor antagonist ketamine disrupt memory functions in rodents. The mechanism by which anesthetic ketamine produces its adverse behavioural effects is not yet clarified. The implication of nicotinic acetylcholine
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门